Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opdivo Gets A Melanoma Rejection, But Also An Expansion

This article was originally published in Scrip

Executive Summary

A drug that looked like it could do no wrong in the FDA's eyes, Bristol-Myers Squibb Co.'s Opdivo (nivolumab), actually got a rejection from the agency to expand the medicine's use as a single agent for previously untreated patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

You may also be interested in...



Array Raring To Go Commercially With First Approval – Mektovi/Braftovi

Array believes that a zero copay offer for patients will help its newly FDA-approved Mektovi/Braftovi combination stand out from the crowd in melanoma and notes that the regimen also has potential in a larger indication – colon cancer.

Novartis' Growth Driver Tafinlar/Mekinist Picks Up New Melanoma, Thyroid Indications

New FDA labeling brings Tafinlar/Mekinist into adjuvant melanoma setting, but Bristol's competing Opdivo already has captured nearly 50% of the market and is approved regardless of genetic mutation.

Opdivo Success In Early Melanoma Paves Way For Other Tumor Types

Study finds that Bristol-Myers Squibb's PD-1 inhibitor Opdivo beats the company's CTLA-4 inhibitor Yervoy in Stage III/C or Stage IV melanoma, spurring hopes for ongoing studies in other tumor types.

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel